Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer

被引：8

作者：

Xiao, Yan ^{[1
,3
]}

Gao, Wencheng ^{[2
]}

机构：

[1] Dongguan Tungwah Hosp, Dept Oncol, Dongguan 523000, Guangdong, Peoples R China

[2] Dongguan Houjie Town Peoples Hosp, Dept Gen Surg, Dongguan 523962, Guangdong, Peoples R China

[3] Dongguan Tungwah Hosp, Dept Oncol, 1 Dongcheng East Rd, Dongguan 523000, Guangdong, Peoples R China

来源：

ONCOLOGY LETTERS | 2022年 / 24卷 / 01期

关键词：

triple-negative breast cancer; chemotherapy; platinum agents; poly(ADP-ribose) polymerase-inhibitors; immunotherapy; programmed cell death protein 1; programmed cell death 1 ligand 1 inhibitors; BRCA status; homologous recombination deficiency score; TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; PLUS CARBOPLATIN; ADJUVANT BREAST; NAB-PACLITAXEL; HIGH-RISK; PHASE-II; CHEMOTHERAPY; WOMEN; IMPACT;

D O I：

10.3892/ol.2022.13340

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) is a heterogeneous disease, accounting for about 15.0-20.0% of all breast cancer cases. TNBC is associated with early recurrence and metastasis, strong invasiveness and a poor prognosis. Chemotherapy is currently the mainstay of treatment for TNBC, and achievement of a pathological complete response is closely associated with a long-term good prognosis. Improving the long-term prognosis in patients with TNBC is a challenge in breast cancer treatment, and more clinical evidence is needed to guide the choice of treatment strategies. The current study reviews the conventional treatment modality for TNBC and the selection of neoadjuvant chemotherapy (NACT) regimens available. The research progress on optimizing NACT regimens is also reviewed, and the uniqueness of the treatment of this breast cancer subtype is emphasized, in order to provide reference for the clinical practice and research with regard to TNBC treatment.

引用

页数：11

共 81 条

[1] Subtyping of Triple-Negative Breast Cancer: Implications for Therapy [J].

Abramson, Vandana G. ;

Lehmann, Brian D. ;

Ballinger, Tarah J. ;

Pietenpol, Jennifer A. .

CANCER, 2015, 121 (01) :8-16

[2] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[3] A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study [J].

Alba, E. ;

Chacon, J. I. ;

Lluch, A. ;

Anton, A. ;

Estevez, L. ;

Cirauqui, B. ;

Carrasco, E. ;

Calvo, L. ;

Segui, M. A. ;

Ribelles, N. ;

Alvarez, R. ;

Sanchez-Munoz, A. ;

Sanchez, R. ;

Lopez Garcia-Asenjo, J. A. ;

Rodriguez-Martin, C. ;

Escudero, M. J. ;

Albanell, J. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) :487-493

[4] Higher Population-Based Incidence Rates of Triple-Negative Breast Cancer Among Young African-American Women Implications for Breast Cancer Screening Recommendations [J].

Amirikia, Kathryn C. ;

Mills, Paul ;

Bush, Jason ;

Newman, Lisa A. .

CANCER, 2011, 117 (12) :2747-2753

[5] Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors [J].

Arora, Sanjeevani ;

Velichinskii, Rodion ;

Lesh, Randy W. ;

Ali, Usman ;

Kubiak, Michal ;

Bansal, Pranshu ;

Borghaei, Hossein ;

Edelman, Martin J. ;

Boumber, Yanis .

ADVANCES IN THERAPY, 2019, 36 (10) :2638-2678

[6] Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer [J].

Atchley, Deann P. ;

Albarracin, Constance T. ;

Lopez, Adriana ;

Valero, Vicente ;

Amos, Christopher I. ;

Gonzalez-Angulo, Ana Maria ;

Hortobagyi, Gabriel N. ;

Arun, Banu K. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4282-4288

[7] Taxanes: impact on breast cancer therapy [J].

Bachegowda, Lohith S. ;

Makower, Della F. ;

Sparano, Joseph A. .

ANTI-CANCER DRUGS, 2014, 25 (05) :512-521

[8] St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment [J].

Balic, Marija ;

Thomssen, Christoph ;

Wuerstlein, Rachel ;

Gnant, Michael ;

Harbeck, Nadia .

BREAST CARE, 2019, 14 (02) :103-110

[9] Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy [J].

Barron, Alison U. ;

Hoskin, Tanya L. ;

Day, Courtney N. ;

Hwang, E. Shelley ;

Kuerer, Henry M. ;

Boughey, Judy C. .

JAMA SURGERY, 2018, 153 (12) :1120-1126

[10] Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer [J].

Baselga, Jose ;

Gomez, Patricia ;

Greil, Richard ;

Braga, Sofia ;

Climent, Miguel A. ;

Wardley, Andrew M. ;

Kaufman, Bella ;

Stemmer, Salomon M. ;

Pego, Antonio ;

Chan, Arlene ;

Goeminne, Jean-Charles ;

Graas, Marie-Pascale ;

Kennedy, M. John ;

Ciruelos Gil, Eva Maria ;

Schneeweiss, Andreas ;

Zubel, Angela ;

Groos, Jutta ;

Melezinkova, Helena ;

Awada, Ahmad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) :2586-+

← 1 2 3 4 5 6 7 8 9 →